A Multicenter, Randomized, Double-Blind, Placebo-Controlled Ph2 Trial of Pacibekitug SC Quarterly or Monthly in Patients with Elevated hs-CRP and Chronic Kidney Disease: TRANQUILITY 90-Day Results
31 August 2025 (15:15 - 16:00)
Organised by: 
About the speaker
Icahn School of Medicine at Mount Sinai, New York City (United States of America)
8 More presentations in this session
Access the full session
The Event
ESC Congress 2025
31 August 2025
15:15 CET
